drugset / Trial / NCT05307705
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.
Timeline
- Start
- 2022-05-11
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LOXO-783 | Unknown | — | Oral |
| Background | Abemaciclib | Small molecule | — | — |
| Background | Anastrozole | Other / unclassified | — | Oral |
| Background | Exemestane | Small molecule | — | Oral |
| Background | Fulvestrant | Small molecule | — | Intramuscular |
| Background | Imlunestrant | Small molecule | — | Oral |
| Background | Letrozole | Other / unclassified | — | Oral |
| Background | Paclitaxel | Small molecule | — | Intravenous |